Journal of Diagnostics Concepts & Practice ›› 2016, Vol. 15 ›› Issue (06): 567-572.doi: 10.16150/j.1671-2870.2016.06.005
• Experts forum • Previous Articles Next Articles
Received:2016-10-19
Online:2016-12-25
Published:2022-07-27
CLC Number:
| [1] Greenberg PL, Attar E, Bennett JM, et al.Myelodysplastic syndromes: clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2013,11(7):838-874. [2] Pang WW, Pluvinage JV, Price EA, et al.Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes[J]. Proc Natl Acad Sci U S A,2013,110(8):3011-3016. [3] Ma X, Does M, Raza A, et al.Myelodysplastic syndromes: incidence and survival in the United States[J]. Cancer,2007,109(8):1536-1542. [4] Kantarjian H, Giles F, List A, et al.The incidence and impact of thrombocytopenia in myelodysplastic syndromes[J]. Cancer,2007,109(9):1705-1714. [5] Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer,2008,113(6):1351-1361. [6] Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes[J]. Am J Hematol,2008,83(10):765-770. [7] Sekeres MA, Schoonen WM, Kantarjian H, et al.Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys[J]. J Natl Cancer Inst,2008,100(21):1542-1551. [8] Goodnough LT, DiPersio JF. Issues in the management of cancer-related thrombocytopenia[J]. Oncology (Williston Park),2002,16(11):1558-1567,1570,1572-1574. [9] Yamada M, Komatsu N, Kirito K, et al.Thrombopoietin supports [10] Kuter DJ.New thrombopoietic growth factors[J]. Clin Lymphoma Myeloma,2009,9(Suppl 3):S347-S356. [11] Kuter DJ.Romiplostim[J]. Cancer Treat Res,2011,157:267-288. [12] Broudy VC, Lin NL.AMG531 stimulates megakaryopoiesis [13] Erickson-Miller C, Tian S, Hopson C, et al.Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115[J]. Transfusion,2005,45S(3):43A. [14] Erickson-Miller CL, Delorme E, Tian SS, et al.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist[J]. Stem Cells,2009, 27(2):424-430. [15] Haselboeck J, Pabinger I, Ay C, et al.Platelet activation and function during eltrombopag treatment in immune thrombocytopenia[J]. Ann Hematol,2012,91(1):109-113. [16] Bussel JB, Kuter DJ, Pullarkat V, et al.Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP[J]. Blood,2009,113(10):2161-2171. [17] Kantarjian H, Fenaux P, Sekeres MA, et al.Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia[J]. J Clin Oncol,2010,28(3):437-444. [18] Sekeres MA, Kantarjian H, Fenaux P, et al.Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes[J]. Cancer,2011,117(5):992-1000. [19] Giagounidis A, Mufti GJ, Fenaux P, et al.Results of a randomized, double-blind study of romiplostim [20] Santini V.Novel therapeutic strategies: hypomethylating agents and beyond[J]. Hematology Am Soc Hematol Educ Program,2012,2012:65-73. [21] Santini V, Fenaux P, Mufti GJ, et al.Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*[J]. Eur J Haematol,2010,85(2):130-138. [22] Kantarjian HM, Giles FJ, Greenberg PL, et al.Phase 2 study of romiplostim in patients with low- or interme-diate-risk myelodysplastic syndrome receiving azacitidine therapy[J]. Blood,2010,116(17):3163-3170. [23] Greenberg PL, Garcia-Manero G, Moore M, et al.A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine[J]. Leuk Lymphoma,2013,54(2):321-328. [24] Jädersten M, Hellström-Lindberg E.Myelodysplastic syndromes: biology and treatment[J]. J Intern Med,2009,265(3):307-328. [25] Mohamedali A, Mufti GJ.Van-den Berghe's 5q- syndrome in 2008[J]. Br J Haematol,2009,144(2):157-168. [26] List A, Dewald G, Bennett J, et al.Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med,2006,355(14):1456-1465. [27] Wang ES, Lyons RM, Larson RA, et al.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide[J]. J Hematol Oncol,2012, 5:71. [28] Prica A, Sholzberg M, Buckstein R.Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials[J]. Br J Haematol,2014,167(5):626-638. [29] Mavroudi I, Pyrovolaki K, Pavlaki K, et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J]. Leuk Res,2011,35(3):323-328. [30] Tamari R, Schinke C, Bhagat T, et al.Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone[J]. Leuk Lymphoma,2014,55(12):2901-2906. [31] Sellers T, Hart T, Semanik M, et al.Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs[J]. Blood,2004,104(111):568A. [32] Jenkins JM, Williams D, Deng Y, et al.Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist[J]. Blood,2007,109(11):4739-4741. [33] Will B, Kawahara M, Luciano JP, et al.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood,2009, 114(18):3899-3908. [34] Svensson T, Chowdhury O, Garelius H, et al.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine[J]. Eur J Haematol,2014,93(5):439-445. [35] Dickinson M, Herbert K, Sardjono C, et al.High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML[J]. Leuk Res,2013,371:S147. [36] Oliva EN, Santini V, Zini G, et al.Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial[J]. Leuk Res,2013,371:S162. [37] Oliva EN, Santini V, Zini G, et al.Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial(EQoL-MDS)[J]. Blood,2012,120(21). [38] Kalina U, Hofmann WK, Koschmieder S, et al.Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes[J]. Exp Hematol,2000,28(10):1158-1163. [39] Luo SS, Ogata K, Yokose N, et al.Effect of thrombo-poietin on proliferation of blasts from patients with myelodysplastic syndromes[J]. Stem Cells,2000,18(2):112-119. [40] Platzbecker U, Wong RS, Verma A, et al.Safety and tole-rability of eltrombopag [41] Will B, Kawahara M, Luciano J P, et al.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Blood,2009, 114(18):3899-3908. [42] Kalota A, Gewirtz AM.A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells[J]. Blood,2010,115(1):89-93. [43] Roth M, Will B, Simkin G, et al.Eltrombopag inhibits the proliferation of leukemia cells [44] Erickson-Miller CL, Kirchner J, Aivado M, et al.Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag[J]. Leuk Res,2010,34(9):1224-1231. [45] Mavroudi I, Pyrovolaki K, Pavlaki K, et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J]. Leuk Res,2011,35(3):323-328. [46] Sugita M, Kalota A, Gewirtz AM, et al.Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression[J]. Leukemia,2013,27(5):1207-1210. |
| [1] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 195-198. |
| [2] | . [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 685-671. |
| [3] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 468-471. |
| [4] | CAO Yafeng, WANG Jing, GU Jun, LU Hongyu, XUN Jie, LIU Yuanfang, WANG Yan, WANG Jin, CHEN Yu, CHEN Yubao, LI Jiaming, HAO Jie, MI Jianqing, CHEN Mei. Analysis of peripheral neuropathy following treatment with bortezomib in 114 newly-diagnosed multiple myeloma patients [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 492-497. |
| [5] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 472-476. |
| [6] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 455-459. |
| [7] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 545-549. |
| [8] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 556-560. |
| [9] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 561-566. |
| [10] | . [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 573-577. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
